JP2023536631A5 - - Google Patents
Info
- Publication number
- JP2023536631A5 JP2023536631A5 JP2023507634A JP2023507634A JP2023536631A5 JP 2023536631 A5 JP2023536631 A5 JP 2023536631A5 JP 2023507634 A JP2023507634 A JP 2023507634A JP 2023507634 A JP2023507634 A JP 2023507634A JP 2023536631 A5 JP2023536631 A5 JP 2023536631A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- seq
- cdr1
- cdr2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063061112P | 2020-08-04 | 2020-08-04 | |
| US63/061,112 | 2020-08-04 | ||
| PCT/US2021/044356 WO2022031710A2 (en) | 2020-08-04 | 2021-08-03 | Multispecific binding agents and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023536631A JP2023536631A (ja) | 2023-08-28 |
| JP2023536631A5 true JP2023536631A5 (enExample) | 2024-08-08 |
| JP7840312B2 JP7840312B2 (ja) | 2026-04-03 |
Family
ID=80120131
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023507634A Active JP7840312B2 (ja) | 2020-08-04 | 2021-08-03 | 多重特異性結合性作用剤およびその使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240010751A1 (enExample) |
| EP (1) | EP4192878A4 (enExample) |
| JP (1) | JP7840312B2 (enExample) |
| CN (1) | CN116390939A (enExample) |
| AU (1) | AU2021322114A1 (enExample) |
| CA (1) | CA3188068A1 (enExample) |
| WO (1) | WO2022031710A2 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL314395A (en) * | 2022-01-31 | 2024-09-01 | Centessa Pharmaceuticals Uk Ltd | Bispecific anti-CD47 and anti-PD-L1 activatable proteins and their uses |
| EP4540290A2 (en) * | 2022-06-14 | 2025-04-23 | Invenra Inc. | Multispecific binding agents that target b7h3 and gd2 and uses thereof |
| WO2024108137A2 (en) * | 2022-11-18 | 2024-05-23 | Seismic Therapeutic, Inc. | Fc fusion molecules and uses thereof |
| JP2026501731A (ja) | 2023-01-06 | 2026-01-16 | サイズミック セラピューティク インコーポレイテッド | プロテアーゼ変異体及びその使用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4209510B1 (en) * | 2008-12-09 | 2024-01-31 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| SG11202003652QA (en) * | 2017-10-27 | 2020-05-28 | Univ New York | Anti-galectin-9 antibodies and uses thereof |
| AU2017439776B2 (en) * | 2017-11-20 | 2025-03-27 | Taizhou Mabtech Pharmaceutical Co., Ltd | Bifunctional fusion protein targeting CD47 and PD-l1 |
| EA202091364A1 (ru) * | 2017-12-04 | 2020-10-13 | Бейджин Ханми Фармасьютикал Ко., Лтд. | Анти-pd-l1/анти-cd47 биспецифическое антитело с подобной природному антителу структурой и в форме гетеродимера и способ его получения |
| WO2019179434A1 (en) * | 2018-03-20 | 2019-09-26 | Wuxi Biologics (Shanghai) Co., Ltd. | Novel bispecific pd-1/cd47 antibody molecules |
| US20230357391A1 (en) * | 2020-08-04 | 2023-11-09 | Exelixis, Inc. | Cd47 binding agents and uses thereof |
| CA3187850A1 (en) * | 2020-08-04 | 2022-02-10 | Bryan Glaser | Pd-l1 binding agents and uses thereof |
-
2021
- 2021-08-03 EP EP21852525.1A patent/EP4192878A4/en active Pending
- 2021-08-03 US US18/018,864 patent/US20240010751A1/en active Pending
- 2021-08-03 WO PCT/US2021/044356 patent/WO2022031710A2/en not_active Ceased
- 2021-08-03 CA CA3188068A patent/CA3188068A1/en active Pending
- 2021-08-03 CN CN202180067259.6A patent/CN116390939A/zh active Pending
- 2021-08-03 JP JP2023507634A patent/JP7840312B2/ja active Active
- 2021-08-03 AU AU2021322114A patent/AU2021322114A1/en active Pending